US · PBLS · BIOTECHNOLOGY
Parabilis Medicines, Inc. (PBLS) intrinsic value and stock valuation
$41.73as of 2026-09-18 · Mkt cap 4.3B
Data updated · price as of 2026-09-18
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Parabilis Medicines, Inc. DCF and intrinsic value
InvestorsCraft values PBLS with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from PBLS’s statements →
Parabilis Medicines, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2025–2024, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| FY | FY | |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Operating income | -$-152.08T | -$-126.13T |
| Net income | -$-145.89T | -$-117.91T |
| EPSd | -$-72.11M | -$-60.96M |
| Operating cash flow | -$-123.71T | -$-103.61T |
| Capital expenditure | -$-306B | -$-879B |
| Free cash flow | -$-124.02T | -$-104.49T |
| Total assets | $80.8T | $149.3T |
| Total debt | $58.7T | $66.2T |
| Net debt | $31T | $18.9T |
| Total equity | -$-16.52T | $56.4T |
| Cash and short-term investments | $27.7T | $88T |
Income statement
| FY | FY | |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Research and development expenses | $125.6T | $100.8T |
| Selling, general and administrative expenses | $26.5T | $25.3T |
| Other expenses | $0.00 | $0.00 |
| Operating expenses | $152.1T | $126.1T |
| Cost and expenses | $152.1T | $126.1T |
| Interest income | $3.39T | $6.41T |
| Interest expense | $1.52T | $1.49T |
| Depreciation and amortization | $2.5T | $2.1T |
| Ebitda | -$-141.87T | -$-114.33T |
| Operating income | -$-152.08T | -$-126.13T |
| Total other income/expenses, net | $6.19T | $8.21T |
| Income before tax | -$-145.89T | -$-117.91T |
| Income tax expense | $0.00 | $0.00 |
| Net income | -$-145.89T | -$-117.91T |
| Weighted average shares outstanding | $2.02T | $1.93T |
| Weighted average diluted shares outstanding | $2.02T | $1.93T |
Balance sheet
| FY | FY | |
|---|---|---|
| Cash and short-term investments | $27.7T | $88T |
| Net receivables | $0.00 | $360B |
| Inventory | $0.00 | $0.00 |
| Total current assets | $29.4T | $92.2T |
| Property, plant and equipment, net | $46.1T | $52.9T |
| Goodwill and intangible assets | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 |
| Total non-current assets | $51.5T | $57T |
| Total assets | $80.8T | $149.3T |
| Accounts payable | $17.3T | $9.51T |
| Short-term debt | $20.9T | $9.38T |
| Deferred revenue | $0.00 | $0.00 |
| Total current liabilities | $56.8T | $32.4T |
| Long-term debt | $37.8T | $56.8T |
| Deferred revenue, non-current | $0.00 | $0.00 |
| Total non-current liabilities | $40.6T | $60.4T |
| Capital lease obligations | $45.6T | $50.9T |
| Total liabilities | $97.3T | $92.8T |
| Common stock | $0.00 | $0.00 |
| Retained earnings | -$-541.5T | -$-395.62T |
| Accumulated other comprehensive income (loss) | $0.00 | $21B |
| Total equity | -$-16.52T | $56.4T |
| Total investments | $0.00 | $40.7T |
| Total debt | $58.7T | $66.2T |
| Net debt | $31T | $18.9T |
Cash flow statement
| FY | FY | |
|---|---|---|
| Net income | -$-145.89T | -$-117.91T |
| Depreciation and amortization | $2.5T | $2.11T |
| Stock-based compensation | $3.32T | $4.31T |
| Change in working capital | $9.12T | $910B |
| Accounts receivable | $360B | $106B |
| Inventory | $0.00 | $0.00 |
| Accounts payable | $13.6T | $9.28T |
| Net cash provided by operating activities | -$-123.71T | -$-103.61T |
| Investments in property, plant and equipment | -$-306B | -$-879B |
| Acquisitions, net | $0.00 | $0.00 |
| Net cash used for investing activities | $39.8T | $30.2T |
| Common stock issued | $67.5T | $78.1T |
| Common stock repurchased | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 |
| Net cash used for financing activities | $64.4T | $78.1T |
| Net change in cash | -$-19.57T | $4.7T |
| Cash at end of period | $30.6T | $50.1T |
| Operating cash flow | -$-123.71T | -$-103.61T |
| Capital expenditure | -$-306B | -$-879B |
| Free cash flow | -$-124.02T | -$-104.49T |
Line items
Line items
Line items
About Parabilis Medicines, Inc.
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
- CEO
- Mathai Mammen
- Employees
- 145
- Beta
- 0.00
Explore
Frequently asked questions
What is the intrinsic value of Parabilis Medicines, Inc. (PBLS)?
Parabilis Medicines, Inc. (PBLS) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is PBLS undervalued?
PBLS trades at a price of $41.73 (Sep 19, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.